Breaking News
October 18, 2018 - 5 Strength-Training Mistakes to Avoid
October 18, 2018 - Immune system’s balancing act keeps bowel disease in check
October 18, 2018 - Anti-inflammatory drug effective for treating lymphedema symptoms | News Center
October 18, 2018 - Keeping Your Voice Young
October 18, 2018 - One-time universal screening recommended to tackle increase in hepatitis C
October 18, 2018 - Researchers to develop new stem cell-based strategies for treating vision disorders
October 18, 2018 - Detecting epigenetic signature may help people stay ahead of inflammatory bowel disease
October 18, 2018 - Understanding AFib: Slowing down the dancing heart
October 18, 2018 - Using NMR to Reduce Fraud
October 18, 2018 - New automated model identifies dense breast tissue in mammograms
October 18, 2018 - Mysterious polio-like illness baffles medical experts while frightening parents
October 18, 2018 - Cases of Acute Flaccid Myelitis on the rise across U.S.
October 18, 2018 - Dietary fiber reduces brain inflammation during aging
October 18, 2018 - New tool could help prioritize recovery efforts for the poorest hit by natural disasters
October 18, 2018 - Hundreds of dietary supplements shown to contain unapproved drugs
October 18, 2018 - Active Pharmaceuticals ID’d in >700 Dietary Supplements
October 18, 2018 - Cell death protein also damps inflammation
October 18, 2018 - Health Highlights: Oct. 15, 2018
October 18, 2018 - Largest study of ‘post-treatment controllers’ reveals clues about HIV remission
October 18, 2018 - Bad Blood in Silicon Valley: A conversation with John Carreyrou
October 18, 2018 - ANTRUK’s Annual Lecture sends out message on shortage of funds for antibiotic research
October 18, 2018 - NAM special publication outlines steps to ensure interoperability of health care systems
October 18, 2018 - Novel method uses just a drop of blood to monitor effect of lung cancer therapy
October 18, 2018 - New blood test could spare cancer patients from unnecessary chemotherapy
October 18, 2018 - Training young researchers to work with data volumes arising in the health sector
October 18, 2018 - New Metrohm IC method is reliable and convenient to use for zinc oxide assay
October 18, 2018 - Global AIDS, TB fight needs more money: health fund
October 18, 2018 - Understanding the forces that cause sports concussions
October 18, 2018 - Research points to new target for treating periodontitis
October 18, 2018 - New tool improves assessment of postpartum depression symptoms
October 18, 2018 - From Biopsy to Diagnosis
October 18, 2018 - Sexual harassment and assault linked to worse physical/mental health among midlife women
October 18, 2018 - Stumped by medical school? A Q&A with a learning specialist
October 18, 2018 - Report predicts life expectancy in 2040, Spain comes out on top
October 18, 2018 - Self-lubricating condoms may help raise condom usage
October 18, 2018 - Targeting immune checkpoints in microglia could reduce out-of-control neuroinflammation
October 18, 2018 - Study finds changes in antiepileptic drug metabolism during different trimesters of pregnancy
October 18, 2018 - Autonomic nervous system directly controls stem cell proliferation, study shows
October 18, 2018 - FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
October 18, 2018 - Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer
October 18, 2018 - Many U.S. adults confused about primary care, study shows
October 18, 2018 - UC researcher focuses on light-mediated therapies to target breast cancer
October 18, 2018 - With philanthropic gifts, Stanford poised to make major advances in neurosciences | News Center
October 18, 2018 - Mice study shows antibiotics are not always necessary to cure sepsis
October 18, 2018 - Researchers discover why heart contractions are weaker in individuals with HCM
October 18, 2018 - Participation in organized sport during childhood may have long-term skeletal benefits
October 18, 2018 - Probiotic/antibiotic combination could eradicate drug-resistant bacteria
October 17, 2018 - More Socioeconomic Challenges for Hispanic Women With HIV
October 17, 2018 - 49,XXXXY syndrome – Genetics Home Reference
October 17, 2018 - Scientists uncover possible new causes of Tourette syndrome
October 17, 2018 - Girl undergoes unusual heart surgery after compassionate-use exemption | News Center
October 17, 2018 - Health Issues That Are Sometimes Mistaken for Gluten Sensitivity
October 17, 2018 - Elective induction of labor at 39 weeks may be beneficial option for women and their babies
October 17, 2018 - New smart watch algorithms can accurately monitor wearers’ sleep patterns
October 17, 2018 - Researchers demonstrate epigenetic memory transmission via sperm
October 17, 2018 - FDA, DHS announce memorandum of agreement to address cybersecurity in medical devices
October 17, 2018 - Health Tip: Know the Risks of Chicken Pox
October 17, 2018 - Immunotherapy effective against hereditary melanoma
October 17, 2018 - Researchers reveal new mechanism for how animal cells stay intact | News Center
October 17, 2018 - Alzheimer's Goes Under the Cryo-Electron Microscope
October 17, 2018 - Medicare for all? CMS chief warns program has enough problems already
October 17, 2018 - Metrohm Raman introduces Mira P handheld Raman system
October 17, 2018 - Expanding the knowledge about hippocampus to better understand cognitive deficits in MS
October 17, 2018 - Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features
October 17, 2018 - Many healthy children may have metabolic risk factors, finds study
October 17, 2018 - A new antibiotic could be a better, faster treatment for tuberculosis
October 17, 2018 - “I will not become a Robot Doctor”: A medical student vows to practice compassion
October 17, 2018 - Study findings may explain sporadic outbreaks of C. difficile infections in hospitals
October 17, 2018 - Purdue researchers develop new chemical process to find better drug ‘fits’ for patients
October 17, 2018 - Yale researchers develop way to attack RNA with small-molecule drugs
October 17, 2018 - New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug
October 17, 2018 - Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
October 17, 2018 - Nine cases of polio-like illness suspected in children in illinois
October 17, 2018 - Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries
October 17, 2018 - Patients once thought incurable can benefit from high-dose radiation therapy
October 17, 2018 - Researchers awarded grant to advance testing of experimental heroin vaccine
October 17, 2018 - Researchers examine SSRI use during pregnancy and major gestational malformations
October 17, 2018 - FDA grants Rare Pediatric Disease Designation for Immusoft’s Iduronicrin genleukocel-T
October 17, 2018 - Reliable Respiratory announces acquisition of Attleboro Area Medical Equipment
October 17, 2018 - Study reveals link between childhood abuse and higher arthritis risk in adulthood
Oral Drug Beats Interferon in First Pediatric MS Trial

Oral Drug Beats Interferon in First Pediatric MS Trial

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

PARIS — In the first randomized controlled trial in pediatric multiple sclerosis, fingolimod (Gilenya) significantly cut relapses compared with interferon beta-1a (Avonex), researchers reported here.

In the PARADIGMS trial, children and adolescents in the fingolimod group had an 82% relative reduction in annualized relapse rate (ARR) over 2 years compared with those on interferon (0.67 versus 0.12, P<0.001), according to Tanuja Chitnis, MD, of Brigham & Women's Hospital in Boston, and colleagues.

They also had significant benefits on MRI markers of disease and in terms of disability, but there were more serious adverse events with fingolimod, Chitnis reported at the joint ECTRIMS-ACTRIMS meeting.

Pediatric patients experience more frequent relapses and are more likely to accumulate physical disability at an earlier age than patients diagnosed as adults, Chitnis said. Some 3% to 5% of all MS patients have a pediatric onset of their disease.

Yet there are no approved drugs for pediatric MS. Clinicians will sometimes use the injectable therapies or some of the safer oral drugs in older children, but there are no data from randomized controlled trials to support specific recommendations.

Chitnis’ group enrolled 215 children and adolescents, mean age 15, with relapsing-remitting MS who had a mean Expanded Disability Status Scale (EDSS) score of 1.5 into the PARADIGMS study. Patients had at least one relapse in the past year or two, relapses in the previous 2 years, or they had evidence of one or more gadolinium-enhancing lesions on MRI within 6 months prior to randomization.

Kids were randomized to weekly injections of interferon or to daily, oral fingolimod up to a dose of 0.5 mg, adjusted for body weight. The study had a flexible duration of up to 2 years, and the study then switched to an open-label design. Most fingolimod patients (93%) and 75% of interferon patients completed the core phase of the study while remaining on the study drug.

In addition to meeting the primary endpoint, fingolimod beat interferon on the key secondary endpoint of time to first confirmed relapse, which was significantly delayed with fingolimod. About 86% of those on the oral drug were free of relapse at 2 years compared with 39% of those on interferon.

On MRI measures, fingolimod patients had a 53% relative reduction in new or enlarging T2 lesions (P<0.001) and a 66% relative reduction in in gadolinium-enhancing lesions (P<0.001).

Fingolimod also did better at reducing the annual rate of brain atrophy over 2 years compared with interferon (-0.48 versus -0.80, P=0.014), and time to 3-month confirmed disability progression (CDP) was significantly delayed with fingolimod — 95% of those on the oral drug were free of 3-month CDP at the end of the study compared with 85% of those on interferon.

There were more serious adverse events in the fingolimod group at about 18% versus 9%. Leukopenia occurred in about 2% of fingolimod patients compared with none in the interferon group, and there were four seizure events with the oral drug but none with interferon. Regular adverse events, however, were more common with interferon.

Jerry Wolinsky, MD, of the University of Texas Health Science Center in Houston, which was a trial site, called the results “impressive,” and said fingolimod drugmaker Novartis will likely get a “favorable review to extend labeling to this age group by regulatory agencies, making use in children supportable by class I evidence.”

John Corboy, MD, of the University of Colorado Denver, said his center starts all their pediatric MS patients on a highly efficacious therapy, usually natalizumab (Tysabri).

“They’re in a much better position to benefit,” he said. “We want their brains to fully fill out their skulls.”

He said that across the U.S., relatively few pediatric MS patients receive treatment at all. “To me, that’s malpractice,” he stated.

The study was supported by Novartis.

Chitnis disclosed relevant relationships with Novartis, Roche, Biogen, Marck, Serono, and Verily.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles